Dublin-listed Open Orphan has reported a loss of €6.5m in respect of last year. The Cathal Friel-headed company completed the merger with Hvivo in January creating a specialist pharma services group. Europe-focused Open Orphan specialises in rare disease and so-called orphan drugs - treatments developed for medical conditions which,because they are so rare, few pharmaceutical companies pursue research into them. The antibody tests offer "best in class" Covid-19antibody testing performance, according to Open Orphan. The company was founded in 2017, with the aim of becoming a leading specialist contract research pharmaceutical services business.

Source: Irish Independent June 24, 2020 06:45 UTC